List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2885193/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
2	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
3	European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update. Bone Marrow Transplantation, 2011, 46, 709-718.	2.4	402
4	Changes in the epidemiological landscape of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2018, 73, i4-i13.	3.0	349
5	Â-Clucan Antigenemia Assay for the Diagnosis of Invasive Fungal Infections in Patients With Hematological Malignancies: A Systematic Review and Meta-Analysis of Cohort Studies From the Third European Conference on Infections in Leukemia (ECIL-3). Clinical Infectious Diseases, 2012, 54, 633-643.	5.8	260
6	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Critical Care, 2010, 14, R222.	5.8	250
7	Collapsing glomerulopathy in a COVID-19 patient. Kidney International, 2020, 98, 228-231.	5.2	240
8	ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplantation, 2012, 47, 846-854.	2.4	222
9	β-Glucan Antigenemia Anticipates Diagnosis of Blood Culture–Negative Intraabdominal Candidiasis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1100-1109.	5.6	183
10	High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function. Antimicrobial Agents and Chemotherapy, 2010, 54, 4360-4367.	3.2	147
11	Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clinical Microbiology and Infection, 2020, 26, 1178-1182.	6.0	138
12	Aspergillus fumigatus-Related Species in Clinical Practice. Frontiers in Microbiology, 2016, 7, 683.	3.5	125
13	Heat Shock Protein 90 Is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus. Eukaryotic Cell, 2012, 11, 1324-1332.	3.4	122
14	Calcineurin as a multifunctional regulator: Unraveling novel functions in fungal stress responses, hyphal growth, drug resistance, and pathogenesis. Fungal Biology Reviews, 2014, 28, 56-69.	4.7	113
15	Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. Clinical Infectious Diseases, 2017, 64, 1619-1621.	5.8	107
16	Multiplex Blood PCR in Combination with Blood Cultures for Improvement of Microbiological Documentation of Infection in Febrile Neutropenia. Journal of Clinical Microbiology, 2010, 48, 3510-3516.	3.9	101
17	Amoebal pathogens as emerging causal agents of pneumonia. FEMS Microbiology Reviews, 2010, 34, 260-280.	8.6	97
18	Risk factors for candidemia: a prospective matched case-control study. Critical Care, 2020, 24, 109.	5.8	92

#	Article	IF	CITATIONS
19	Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clinical Microbiology and Infection, 2020, 26, 1706-1708.	6.0	90
20	Early diagnosis of invasive mould infections and disease. Journal of Antimicrobial Chemotherapy, 2017, 72, i19-i28.	3.0	87
21	Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	82
22	Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 4308-4311.	3.2	78
23	<i>In Vitro</i> Activity of Calcineurin and Heat Shock Protein 90 Inhibitors against Aspergillus fumigatus Azole- and Echinocandin-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 1035-1039.	3.2	74
24	Identification of a Key Lysine Residue in Heat Shock Protein 90 Required for Azole and Echinocandin Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2014, 58, 1889-1896.	3.2	68
25	Therapeutic Challenges of Non- <i>Aspergillus</i> Invasive Mold Infections in Immunosuppressed Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	68
26	The Candida auris Alert: Facts and Perspectives. Journal of Infectious Diseases, 2018, 217, 516-520.	4.0	66
27	Diagnosis and treatment of invasive fungal infections: looking ahead. Journal of Antimicrobial Chemotherapy, 2019, 74, ii27-ii37.	3.0	66
28	Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. Journal of Infection, 2020, 81, 131-146.	3.3	62
29	Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis. Frontiers in Microbiology, 2015, 6, 96.	3.5	61
30	Phosphorylation of Calcineurin at a Novel Serine-Proline Rich Region Orchestrates Hyphal Growth and Virulence in Aspergillus fumigatus. PLoS Pathogens, 2013, 9, e1003564.	4.7	60
31	Transcriptional Activation of Heat Shock Protein 90 Mediated Via a Proximal Promoter Region as Trigger of Caspofungin Resistance in Aspergillus fumigatus. Journal of Infectious Diseases, 2014, 209, 473-481.	4.0	57
32	Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis. Journal of Fungi (Basel, Switzerland), 2016, 2, 22.	3.5	55
33	Potential Microbiological Effects of Higher Dosing of Echinocandins. Clinical Infectious Diseases, 2015, 61, S669-S677.	5.8	53
34	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp> gal infections Definitions in <scp>ICU</scp> patients ( <scp>FUNDICU</scp> ) project. Mycoses, 2019, 62, 310-319.	4.0	53
35	Heat shock protein 90 (Hsp90): A novel antifungal target againstAspergillus fumigatus. Critical Reviews in Microbiology, 2014, 42, 1-12.	6.1	52
36	Navigating the Uncertainties of COVID-19–Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis. Journal of Infectious Diseases, 2021, , .	4.0	50

#	Article	IF	CITATIONS
37	Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. Clinical Infectious Diseases, 2022, 75, 534-544.	5.8	47
38	Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC. Clinical Infectious Diseases, 2021, 72, S79-S88.	5.8	45
39	Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir. Antimicrobial Agents and Chemotherapy, 2009, 53, 3017-3023.	3.2	43
40	Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds. Journal of Clinical Microbiology, 2015, 53, 3176-3181.	3.9	42
41	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 3413-3422.	3.0	40
42	Monitoring Procalcitonin in Febrile Neutropenia: What Is Its Utility for Initial Diagnosis of Infection and Reassessment in Persistent Fever?. PLoS ONE, 2011, 6, e18886.	2.5	39
43	Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 4946-4955.	3.2	39
44	Validation and clinical application of a multiplex high performance liquid chromatography – tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1157, 122160.	2.3	38
45	Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies. Antimicrobial Agents and Chemotherapy, 2009, 53, 785-787.	3.2	37
46	Nonmolecular Methods for the Diagnosis of Respiratory Fungal Infections. Clinics in Laboratory Medicine, 2014, 34, 315-336.	1.4	37
47	Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. Journal of Antimicrobial Chemotherapy, 2015, 70, 1408-1411.	3.0	37
48	Novel <i>ERG11</i> and <i>TAC1b</i> Mutations Associated with Azole Resistance in Candida auris. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	36
49	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 17.	3.5	36
50	Fastidious intracellular bacteria as causal agents of community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2010, 8, 775-790.	4.4	35
51	Calcineurin-Mediated Regulation of Hyphal Growth, Septation, and Virulence in Aspergillus fumigatus. Mycopathologia, 2014, 178, 341-348.	3.1	35
52	The Aspergillus fumigatus septins play pleiotropic roles in septation, conidiation, and cell wall stress, but are dispensable for virulence. Fungal Genetics and Biology, 2015, 81, 41-51.	2.1	35
53	Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection, 2020, 48, 761-766.	4.7	33
54	COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?. Clinical Microbiology and Infection, 2021, 27, 1376-1378.	6.0	33

#	Article	IF	CITATIONS
55	<i>Parachlamydia</i> and <i>Rhabdochlamydia</i> in Premature Neonates. Emerging Infectious Diseases, 2009, 15, 2072-2075.	4.3	32
56	Cytomegalovirus infection and newâ€onset postâ€ŧransplant diabetes mellitus. Clinical Transplantation, 2008, 22, 245-249.	1.6	30
57	Isavuconazole brain penetration in cerebral aspergillosis. Journal of Antimicrobial Chemotherapy, 2019, 74, 1751-1753.	3.0	30
58	Assessment of the Role of 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults. Clinical Infectious Diseases, 2021, 72, S102-S108.	5.8	30
59	Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. Journal of Clinical Microbiology, 2016, 54, 1638-1640.	3.9	28
60	Invasive Aspergillosis Due to <i>Aspergillus</i> Section <i>Usti</i> : A Multicenter Retrospective Study. Clinical Infectious Diseases, 2021, 72, 1379-1385.	5.8	28
61	First case of Candida auris in Switzerland: discussion about preventive strategies. Swiss Medical Weekly, 2018, 148, w14622.	1.6	28
62	Transcriptomic Signature Differences BetweenÂSARS-CoV-2 and Influenza Virus Infected Patients. Frontiers in Immunology, 2021, 12, 666163.	4.8	27
63	Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult. Swiss Medical Weekly, 2020, 150, w20387.	1.6	27
64	Parachlamydia and Rhabdochlamydia: Emerging Agents of Community-Acquired Respiratory Infections in Children. Clinical Infectious Diseases, 2011, 53, 500-501.	5.8	26
65	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. Haematologica, 2018, 103, e527-e530.	3.5	26
66	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. Open Forum Infectious Diseases, 2020, 7, ofaa075.	0.9	26
67	Ability of quantitative PCR to discriminate Pneumocystis jirovecii pneumonia from colonization. Journal of Medical Microbiology, 2020, 69, 705-711.	1.8	26
68	Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 4727-4733.	3.2	25
69	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. BMC Infectious Diseases, 2021, 21, 296.	2.9	24
70	Case Report: Human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. Journal of Medical Virology, 2008, 80, 1804-1807.	5.0	22
71	Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. BMC Infectious Diseases, 2010, 10, 2.	2.9	21
72	Ultra-Performance Liquid Chromatography Mass Spectrometry and Sensitive Bioassay Methods for Quantification of Posaconazole Plasma Concentrations after Oral Dosing. Antimicrobial Agents and Chemotherapy, 2010, 54, 5074-5081.	3.2	21

#	Article	IF	CITATIONS
73	Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS). Clinical Microbiology and Infection, 2018, 24, 1214.e1-1214.e4.	6.0	20
74	Low-dose Cidofovir for the Treatment of Polyomavirus-Associated Nephropathy: Two Case Reports and Review of the Literature. Antiviral Therapy, 2008, 13, 1001-1009.	1.0	20
75	Let's add invasive aspergillosis to the list of influenza complications. Lancet Respiratory Medicine,the, 2018, 6, 733-735.	10.7	19
76	Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis. Journal of Clinical Microbiology, 2020, 58, .	3.9	19
77	Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection. Transplant Infectious Disease, 2010, 12, 269-272.	1.7	17
78	Immunogenetics of invasive aspergillosis. Medical Mycology, 2011, 49, S125-S136.	0.7	17
79	Polymorphisms in Tumor Necrosis Factor-α Increase Susceptibility to Intra-Abdominal Candida Infection in High-Risk Surgical ICU Patients*. Critical Care Medicine, 2014, 42, e304-e308.	0.9	17
80	Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection. Infection, 2010, 38, 249-253.	4.7	16
81	Link between Heat Shock Protein 90 and the Mitochondrial Respiratory Chain in the Caspofungin Stress Response of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
82	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. International Journal of Antimicrobial Agents, 2009, 34, 386-388.	2.5	15
83	Incidentally discovered COVID-19 pneumonia: the role of diagnostic imaging. European Radiology, 2020, 30, 5211-5213.	4.5	15
84	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. Open Forum Infectious Diseases, 2021, 8, ofab471.	0.9	15
85	Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris. Antimicrobial Agents and Chemotherapy, 2022, 66, e0006722.	3.2	15
86	Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clinical Transplantation, 2010, 24, 794-800.	1.6	14
87	Identification and mutational analyses of phosphorylation sites of the calcineurin-binding protein CbpA and the identification of domains required for calcineurin binding in Aspergillus fumigatus. Frontiers in Microbiology, 2015, 6, 175.	3.5	14
88	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. Journal of Infection, 2018, 76, 489-495.	3.3	13
89	Efficacy of Antifungal Monotherapies and Combinations against Aspergillus calidoustus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
90	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. Mycoses, 2021, 64, 1512-1520.	4.0	11

#	Article	IF	CITATIONS
91	High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies. Clinical Infectious Diseases, 2022, 75, 330-333.	5.8	11
92	Waddlia: An emerging pathogen and a model organism to study the biology of chlamydiae. Microbes and Infection, 2015, 17, 732-737.	1.9	10
93	Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report. Journal of Antimicrobial Chemotherapy, 2019, 74, 2626-2630.	3.0	10
94	Diagnostic approach to encephalitis and meningoencephalitis in adult returning travellers. Clinical Microbiology and Infection, 2019, 25, 415-421.	6.0	10
95	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open, 2021, 11, e049232.	1.9	10
96	Clinical Relevance and Characteristics of Aspergillus calidoustus and Other Aspergillus Species of Section Usti. Journal of Fungi (Basel, Switzerland), 2020, 6, 84.	3.5	9
97	Invasive aspergillosis in coronavirus disease 2019: a practical approach for clinicians. Current Opinion in Infectious Diseases, 2022, 35, 163-169.	3.1	9
98	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses, 2022, 14, 1089.	3.3	9
99	On track to limit antifungal overuse!. Intensive Care Medicine, 2009, 35, 582-584.	8.2	8
100	Heat Shock Protein 90 (Hsp90) in Fungal Growth and Pathogenesis. Current Fungal Infection Reports, 2014, 8, 296-301.	2.6	8
101	Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature. BMC Infectious Diseases, 2020, 20, 527.	2.9	8
102	What Is the Impact of Late-Onset Cytomegalovirus Disease After Valganciclovir Prophylaxis in Kidney Transplantation?. Transplantation, 2008, 86, 1323-1324.	1.0	7
103	Role of biâ€weekly serum galactomannan screening for the diagnosis of invasive aspergillosis in haematological cancer patients. Mycoses, 2018, 61, 350-354.	4.0	7
104	Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature. Antiviral Therapy, 2008, 13, 1001-9.	1.0	7
105	Distribution of <i>Aspergillus</i> Species and Prevalence of Azole Resistance in Respiratory Samples From Swiss Tertiary Care Hospitals. Open Forum Infectious Diseases, 2022, 9, ofab638.	0.9	7
106	Imipenem underdosing as a cause of persistent neutropenic fever?. Journal of Antimicrobial Chemotherapy, 2009, 64, 665-667.	3.0	6
107	Invasive Pulmonary Aspergillosis Goes Viral Again?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 275-277.	5.6	6
108	Editorial: Advances in Aspergillus fumigatus Pathobiology. Frontiers in Microbiology, 2016, 7, 43.	3.5	5

#	Article	IF	CITATIONS
109	Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia. Intensive Care Medicine, 2017, 43, 935-939.	8.2	5
110	Invasive Hormographiella aspergillata infection in patients with acute myeloid leukemia: Report of two cases successfully treated and review of the literature. Medical Mycology Case Reports, 2021, 32, 68-72.	1.3	5
111	Aspergillus tubingensis Endocarditis: A Case Report and Review of the Literature. Mycopathologia, 2022, 187, 249-258.	3.1	5
112	Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients. Medical Mycology, 2021, 59, 93-101.	0.7	4
113	Assessment of the In Vitro and In Vivo Antifungal Activity of NSC319726 against Candida auris. Microbiology Spectrum, 2021, , e0139521.	3.0	4
114	Blood samples drawn for culture as a surrogate marker for case-mix adjustment of hospital antibiotic use. Clinical Microbiology and Infection, 2007, 13, 454-456.	6.0	3
115	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2019, 74, 532-533.	3.0	3
116	COVID-19 Pandemics. Circulation: Cardiovascular Imaging, 2020, 13, e011395.	2.6	3
117	High prevalence of peribronchial focal lesions of airway invasive aspergillosis in hematological cancer patients with prolonged neutropenia. British Journal of Radiology, 2020, 93, 20190693.	2.2	3
118	Insights in the molecular mechanisms of an azole stress adapted laboratory-generated Aspergillus fumigatus strain. Medical Mycology, 2021, 59, 763-772.	0.7	3
119	Limited Index of Clinical Suspicion and Underdiagnosis of Histopathologically Documented Invasive Mold Infections. Open Forum Infectious Diseases, 2021, 8, ofab174.	0.9	3
120	Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period. Journal of Infection, 2022, 84, 722-746.	3.3	3
121	How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	3.9	3
122	Letter on "(1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial― Critical Care, 2021, 25, 55.	5.8	2
123	Pancreatitis, hypereosinophilia and bilateral pulmonary infiltrates as presentation of acute Q fever. New Microbes and New Infections, 2021, 43, 100940.	1.6	2
124	The unresolved issues in the management of mucormycosis. European Journal of Internal Medicine, 2022, 100, 29-30.	2.2	2
125	Frequency and causes of antifungal treatment changes in allogeneic haematopoÃ <sup>-</sup> etic cell transplant recipients with invasive mould infections. Mycoses, 2022, 65, 199-210.	4.0	2
126	Case Report: SARS-CoV-2 as an unexpected causal agent of isolated febrile hepatitis. F1000Research, 2021, 10, 400.	1.6	1